---
title: "Voyah Pharmaceuticals surged 57% after receiving a 60% premium offer from WUXI XDC for acquisition"
description: "Voyah received a 60% premium takeover offer from WUXI XDC. After resuming trading, the stock price peaked at HKD 3.97 and is currently reported at HKD 3.93, up 57.2%. WUXI XDC plans to acquire all sha"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/272626450.md"
published_at: "2026-01-15T01:33:10.000Z"
---

# Voyah Pharmaceuticals surged 57% after receiving a 60% premium offer from WUXI XDC for acquisition

> Voyah received a 60% premium takeover offer from WUXI XDC. After resuming trading, the stock price peaked at HKD 3.97 and is currently reported at HKD 3.93, up 57.2%. WUXI XDC plans to acquire all shares of Voyah using internal resources at a cash price of HKD 4 per share. After the transaction, Voyah will become a subsidiary of WUXI XDC and WuXi Biologics, continuing to be listed on the Hong Kong Stock Exchange. This transaction will help WUXI XDC expand its manufacturing capacity in China and strengthen its market position

Voyah (01875.HK) received a premium offer of 60% from WUXI XDC (02268.HK) for a takeover. After resuming trading this morning (15th), the stock reached a high of HKD 3.97, currently reported at HKD 3.93, up 57.2%, with a trading volume of 2.8 million shares, involving HKD 11.0256 million.

Voyah, WuXi Biologics (02269.HK), and WUXI XDC jointly announced that WUXI XDC, as the offeror, has made a voluntary offer to acquire all shares of Voyah at a cash price of HKD 4 per share, representing a 60% premium over the last closing price before the suspension. Including the cancellation price of stock options, the maximum cost is approximately HKD 2.79 billion, and the offeror intends to pay using internal resources.

WUXI XDC stated that upon completion of the transaction, Voyah will become a subsidiary of WUXI XDC and WuXi Biologics, while Voyah will continue to be listed on the Hong Kong Stock Exchange and plans to nominate new directors.

WUXI XDC believes that acquiring Voyah will expand and acquire additional operational manufacturing capacity in China. This transaction also aligns with WUXI XDC's ongoing business development plan, helping to further enrich its project portfolio and expand its customer base. The transaction will further strengthen WUXI XDC's leading market position in the field of contract development and manufacturing organizations for antibody-drug conjugates

### Related Stocks

- [01875.HK - BIODLINK-B](https://longbridge.com/en/quote/01875.HK.md)
- [02268.HK - WUXI XDC](https://longbridge.com/en/quote/02268.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 野村證券將藥明合聯開曼的目標價從 82.72 港元上調至 87.73 港元，並維持買入評級 | 野村將藥明合聯（WuXi XDC Cayman）的目標價從 82.72 港元上調至 87.73 港元，維持 “買入” 評級 | [Link](https://longbridge.com/en/news/275736820.md) |
| 藥明合聯發佈了現金收購 TOT BIOPHARM 的要約文件 | WuXi XDC Cayman Inc. 已經發出了自願現金收購 TOT BIOPHARM International Co. Ltd. (HK:1875) 的要約文件，排除已由要約方持有的股份。該要約將於 2026 年 2 月 12 日開 | [Link](https://longbridge.com/en/news/275675866.md) |
| 簡訊：藥明合聯發盈喜 料去年盈利增 38% | 藥明合聯生物技術有限公司預計 2025 年全年收入同比上升 45%，淨利潤增 38%，主要因優化產品及服務利潤率和有效成本控制。公司還提出以每股 4 港元收購東曜藥業，總額約 27.9 億港元，收購價較停牌前高出 60%。藥明合聯股價跌 2 | [Link](https://longbridge.com/en/news/272635750.md) |
| 藥明合聯開曼表示，預計全年收入將增長超過 45% | 藥明合聯開曼公司：預計財年收入將增長超過 45%，預計財年淨利潤將增長超過 38% | [Link](https://longbridge.com/en/news/272576507.md) |
| 早盤趨勢｜藥明合聯底部拉鋸，短線修復要來了嗎？ | 藥明合聯昨日收盤走勢延續膠着，全天低位徘徊明顯，主力資金參與熱情有限。近期港股醫藥服務股消息面整體安靜，市場等待行業政策明朗化，板塊整體承壓，短期分時波動受制於主力觀望情緒。 公司上一週傳出了研發管線新節點進展，但市場僅給予短暫反應。當前技 | [Link](https://longbridge.com/en/news/270592156.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.